Revista Panamericana de Salud Pública
On-line version ISSN 1680-5348Print version ISSN 1020-4989
CONSTENLA, Dagna et al. Assessment of the economic impact of the antiretroviral vaccine in Venezuela. Rev Panam Salud Publica [online]. 2006, vol.20, n.4, pp.213-222. ISSN 1680-5348. http://dx.doi.org/10.1590/S1020-49892006000900001.
OBJECTIVE: To assess the cost of medical care for rotavirus gastroenteritis and the cost-effectiveness of the antiretroviral vaccine in Venezuelan children under five. METHODS: We used an economic model that comprises epidemiologic information, vaccine efficacy, and the cost of medical care in connection with rotavirus gastroenteritis, viewed from a social perspective. In order to determine the effectiveness of the vaccine, we estimated the number of hospitalized cases, of medical visits, and of deaths averted after vaccination. The cost-effectiveness of the vaccine was determined on the basis of the number of disability-adjusted life years (DALYs) and cases averted. RESULTS: In Venezuela, health services spend approximately US$ 4.2 million yearly on covering the costs of medical care for rotavirus-related disease. In a vaccinated cohort, an antiretroviral vaccination program would prevent around 52% (186) of the deaths, 54% (7 232) of the hospitalizations, and 50% (55 168) of the ambulatory visits that take place during the first five years of life. For an estimated cost of approximately US$ 24 per individual vaccination schedule, the cost-effectiveness ratio obtained is US$ 1 352 per DALY. CONCLUSIONS: The results of this study suggest that antiretroviral vaccination is a cost-effective strategy for preventing rotavirus gastroenteritis in Venezuela, since it can prevent deaths and DALYs in the population under five years of age.
Keywords : Rotavirus; vaccination; cost-effectiveness evaluation; prevention; gastroenteritis; Venezuela.